专利检索 ipc:C07C235/36 第 6 页

51.

发明授权
Catechol derivatives and pharmaceutical preparations containing same 失效
标题翻译：儿茶酚衍生物和含有它的药物制剂

公开(公告)号：US5232923A

公开(公告)日：1993-08-03

申请号：US689098

申请日：1991-04-22

申请人： Nobuyuki Fukazawa , Kengo Otsuka , Shimada Shizuo , Yukio Miyama , Fumiaki Ikeda , Tatsuo Kaiho

发明人： Nobuyuki Fukazawa , Kengo Otsuka , Shimada Shizuo , Yukio Miyama , Fumiaki Ikeda , Tatsuo Kaiho

IPC分类号： C07C235/34 , C07C235/36 , C07C235/38 , C07D207/16 , C07D211/60 , C07D295/185

CPC分类号： C07D295/185 , C07C235/34 , C07C235/36 , C07C235/38 , C07D207/16 , C07D211/60 , C07C2101/14 , C07C2103/74

摘要： Catechol derivatives which produce nerve growth factor in particular tissues of the brain are disclosed. These derivatives provide preventive and therapeutic effects for regressive disorders of the central nervous system including senile dementia of the Alzheimer type.

摘要翻译： 公开了在脑的特定组织中产生神经生长因子的儿茶酚衍生物。这些衍生物为包括阿尔茨海默氏型老年性痴呆的中枢神经系统的退行性疾病提供预防和治疗作用。

52.

发明授权
Butenoic or propenoic acid derivative 失效
标题翻译：丁烯酸或丙烯酸衍生物

公开(公告)号：US5177089A

公开(公告)日：1993-01-05

申请号：US557713

申请日：1990-07-25

申请人： Norio Minami , Fumihiro Ozaki , Keiji Ishibashi , Yasuhiro Kabasawa , Megumi Ikemori , Toshiaki Ogawa , Takanori Kawamura

发明人： Norio Minami , Fumihiro Ozaki , Keiji Ishibashi , Yasuhiro Kabasawa , Megumi Ikemori , Toshiaki Ogawa , Takanori Kawamura

IPC分类号： C07C233/40 , C07C235/34 , C07C235/36 , C07C237/12 , C07C237/20 , C07C255/41 , C07C255/57 , C07C317/44 , C07C323/62 , C07D207/08 , C07D207/32 , C07D207/327 , C07D207/38 , C07D211/22 , C07D211/34 , C07D211/58 , C07D211/86 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/68 , C07D223/16 , C07D233/66 , C07D235/06 , C07D237/14 , C07D241/18 , C07D263/32 , C07D277/30 , C07D317/58 , C07D317/60 , C07D319/18 , C07D405/06 , C07D471/04 , C07D521/00

CPC分类号： C07D207/08 , C07C233/40 , C07C235/34 , C07C235/36 , C07C237/12 , C07C237/20 , C07C255/41 , C07C255/57 , C07C317/44 , C07C323/62 , C07D207/327 , C07D207/38 , C07D211/22 , C07D211/34 , C07D211/58 , C07D211/86 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/68 , C07D223/16 , C07D231/12 , C07D233/56 , C07D235/06 , C07D237/14 , C07D241/18 , C07D249/08 , C07D263/32 , C07D277/30 , C07D317/58 , C07D317/60 , C07D319/18 , C07D405/06 , C07D471/04 , C07C2101/08

摘要： A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydroben or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field. ##STR1##

摘要翻译： 具有下式的丁烯酸或丙烯酸衍生物，其中G是芳基或杂环，R11和R12是氢化或烷基，X是硫或氧，R2和R3是氢，取代基如烷基和J 在这里提供吡啶基或具有取代基的苯基和可以在R2，R3和J之间形成杂环，并且在药理学领域是有用的。（二）

53.

发明授权
Manumycin derivatives and the use thereof 失效
标题翻译：苹果酸衍生物及其用途

公开(公告)号：US5079263A

公开(公告)日：1992-01-07

申请号：US278885

申请日：1988-12-02

申请人： Axel Zeeck , Ralf Thiericke , Hans Zahner , Gerhard Dickneite , Hans H. Sedlacek

发明人： Axel Zeeck , Ralf Thiericke , Hans Zahner , Gerhard Dickneite , Hans H. Sedlacek

IPC分类号： C12P13/02 , A61K31/135 , A61K31/165 , A61P11/00 , A61P29/00 , A61P43/00 , C07C233/32 , C07C235/36 , C07C237/20 , C07C237/22 , C12N9/99 , C12R1/465

CPC分类号： C07C237/22 , C07C235/36 , C07C237/20 , C07C2101/10

摘要： R.sup.2 is H or OH;R.sup.3 is H, OH, OCH.sub.3, CH.sub.3 or NH.sub.2 ;Rhu 4 is H, OH, OCH.sub.3, NH.sub.2 or ##STR2## The compounds of the formula I are prepared by fermentation of the strain Streptomyces parvulus DSM 40722 in the presence of substituted benzoic acids of the general formula II ##STR3## where R.sup.1 is H or OH;R.sup.2 is H or OH;R.sup.3 is H, OH, OCH.sub.3, CH.sub.3 or NH.sub.2 ;R.sup.4 is H, OH, OCH.sub.3 or NH.sub.2,and they inhibit Leukocyte elastase and can be used as pharmaceuticals.

摘要翻译： 其中R1是H或OH; R2是H或OH; R3是H，OH，OCH3，CH3或NH2; R 4是H，OH，OCH 3，NH 2或者其中R 1是通式II的取代苯甲酸存在下，通过菌株Streptomyces parvulus DSM 40722的发酵来制备式I化合物，其中R 1是 H或OH; R2是H或OH; R3是H，OH，OCH3，CH3或NH2; R4是H，OH，OCH3或NH2，它们抑制白细胞弹性蛋白酶，可用作药物。

54.

发明授权
Diaryl butyric acid derivative and pharmaceutical use thereof 失效
标题翻译：二芳基丁酸衍生物及其药物用途

公开(公告)号：US4766116A

公开(公告)日：1988-08-23

申请号：US810591

申请日：1985-12-19

申请人： Toshio Tatsuoka , Kenji Suzuki , Kayoko Imao , Kunihiro Sumoto

发明人： Toshio Tatsuoka , Kenji Suzuki , Kayoko Imao , Kunihiro Sumoto

IPC分类号： C07D207/27 , A61K31/135 , A61K31/16 , A61K31/165 , A61K31/195 , A61K31/22 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/404 , A61K31/495 , A61K31/535 , A61K31/5375 , A61K31/54 , A61P3/06 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , A61P25/28 , C07C67/00 , C07C213/00 , C07C219/10 , C07C219/22 , C07C219/26 , C07C235/18 , C07C235/32 , C07C235/34 , C07C235/36 , C07D209/14 , C07D209/16 , C07D211/16 , C07D211/26 , C07D211/56 , C07D213/40 , C07D213/75 , C07D243/08 , C07D295/10 , C07D295/12 , C07D295/13 , C07D295/16 , C07D295/18 , C07D295/185 , C07D295/22 , C07D295/32 , C07D313/08 , C07C103/82 , C07C103/84

CPC分类号： C07D213/40 , C07D209/16 , C07D295/13 , C07D295/185 , C07D295/32 , C07D313/08

摘要： A diaryl butyric acid derivative having the general formula: ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, or an acyl group having 2 to 4 carbon atoms; R.sup.2 represents an alkyl group having 1 to 3 carbon atoms; andX represents a variety of substituents.This diaryl butyric acid derivative or the pharmaceutically acceptable salt thereof can be prepared by reacting a benzoxepin derivative having the general formula: ##STR2## wherein R.sup.2 is the same as defined above with an amine or alcohol derivative having the general formula;X--Hwherein X is the same as defined above in the presence of an acid catalyst at room temperature or at an elevated temperature and, optionally, further reading the reaction product with an alkylation agent having 1 to 3 carbon atoms or an acylation agent having 2 to 4 carbon atoms.This diaryl butyric acid derivative or the pharmaceutically acceptable salt thereof is effective for ameliorating or treating various symptoms based on cerebral organic disorders and pathergasia.

摘要翻译： 具有以下通式的二芳基丁酸衍生物：其中R 1表示氢原子，具有1至3个碳原子的烷基或具有2至4个碳原子的酰基; R 2表示碳原子数1〜3的烷基。 X表示各种取代基。该二芳基丁酸衍生物或其药学上可接受的盐可以通过使具有以下通式的苯并恶庚英衍生物：其中R2与上述定义相同，具有通式的胺或醇衍生物： XH其中X在酸催化剂存在下，在室温或升高的温度下与上述定义相同，并且任选地进一步用具有1至3个碳原子的烷基化试剂或具有2至 4个碳原子。该二芳基丁酸衍生物或其药学上可接受的盐对于改善或治疗基于脑部有机疾病和麻醉的各种症状是有效的。

55.

发明授权
Hydroquinone ether compounds 失效
标题翻译：对苯醌醚化合物

公开(公告)号：US4631252A

公开(公告)日：1986-12-23

申请号：US741888

申请日：1985-06-06

申请人： Frederick H. Howell

发明人： Frederick H. Howell

IPC分类号： C07C309/24 , C07C43/20 , C07C43/23 , C07C43/257 , C07C45/00 , C07C59/52 , C07C59/64 , C07C66/00 , C07C67/00 , C07C69/734 , C07C201/00 , C07C205/34 , C07C205/37 , C07C209/00 , C07C217/62 , C07C233/18 , C07C233/47 , C07C235/28 , C07C235/34 , C07C235/36 , C07C235/38 , C07C255/33 , C07C255/35 , C07C255/37 , C07C255/40 , C07C255/42 , C07C309/82 , C07C317/22 , C07C317/32 , C07C317/46 , C07C323/16 , C07C323/20 , C07D307/06 , C07D307/12 , C07D309/06 , C07D311/04 , C07F9/40 , C07F9/572 , C07F9/59 , G03C7/26 , G03C7/392 , G03C7/38

CPC分类号： C07C255/00 , C07C217/62 , C07C59/64 , C07C66/00 , C07D307/12 , C07D311/04 , C07F9/4056 , G03C7/39232

摘要： New hydroquinone ether compounds of formula I are described: ##STR1## wherein p is 1 or 2 and q is 0 or 1, provided that p+q is 1 or 2, R is a residue of formula II ##STR2## and R.sub.o, R.sub.oo, R.sub.1, R.sub.2, R.sub.3, Q, n and k are as defined in the specification.The new compounds are useful e.g. as stabilizers in photographic material.

摘要翻译： 描述了式I的新的氢醌醚化合物：其中p为1或2，q为0或1，条件是p + q为1或2，R为式II的残基（IMAGE）（I） II）和Ro，Roo，R1，R2，R3，Q，n和k如说明书中所定义。新化合物是有用的。作为照相材料中的稳定剂。

56.

发明授权
Hydroquinone ether compounds 失效

公开(公告)号：US4549015A

公开(公告)日：1985-10-22

申请号：US504283

申请日：1983-06-14

申请人： Frederick H. Howell

发明人： Frederick H. Howell

IPC分类号： C07C309/24 , C07C43/20 , C07C43/23 , C07C43/257 , C07C45/00 , C07C59/52 , C07C59/64 , C07C66/00 , C07C67/00 , C07C69/734 , C07C201/00 , C07C205/34 , C07C205/37 , C07C209/00 , C07C217/62 , C07C233/18 , C07C233/47 , C07C235/28 , C07C235/34 , C07C235/36 , C07C235/38 , C07C255/33 , C07C255/35 , C07C255/37 , C07C255/40 , C07C255/42 , C07C309/82 , C07C317/22 , C07C317/32 , C07C317/46 , C07C323/16 , C07C323/20 , C07D307/06 , C07D307/12 , C07D309/06 , C07D311/04 , C07F9/40 , C07F9/572 , C07F9/59 , G03C7/26 , G03C7/392 , C07C65/03 , C07C69/708 , C07C103/76

CPC分类号： C07C255/00 , C07C217/62 , C07C59/64 , C07C66/00 , C07D307/12 , C07D311/04 , C07F9/4056 , G03C7/39232

摘要： New hydroquinone ether compounds of formula I are described: ##STR1## wherein p is 1 or 2 and q is 0 or 1, provided that p+q is 1 or 2, R is a residue of formula II ##STR2## and R.sub.o, R.sub.oo, R.sub.1, R.sub.2, R.sub.3, Q, n and k are as defined in the specification.The new compounds are useful e.g. as stabilizers in photographic material.

57.

发明公开
COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS 审中-公开

公开(公告)号：US20240239739A1

公开(公告)日：2024-07-18

申请号：US17870490

申请日：2022-07-21

申请人： AurimMed Pharma, Inc.

发明人： Amir Pesyan , Manuel F. Balandrin

IPC分类号： C07C233/11 , A61P25/16 , A61P25/28 , C07C233/58 , C07C235/28 , C07C235/34 , C07C235/36 , C07C237/20 , C07C237/22 , C07C255/54 , C07D207/16 , C07D211/16 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/643 , C07D295/155 , C07D295/185 , C07D307/81 , C07D317/60 , C07D319/18

CPC分类号： C07C233/11 , A61P25/16 , A61P25/28 , C07C233/58 , C07C235/28 , C07C235/34 , C07C235/36 , C07C237/20 , C07C237/22 , C07C255/54 , C07D207/16 , C07D211/16 , C07D211/60 , C07D211/62 , C07D213/56 , C07D213/61 , C07D213/643 , C07D295/155 , C07D295/185 , C07D307/81 , C07D317/60 , C07D319/18

摘要： A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.